Dalia Regue-Raich

Badalona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications

Optimized ACE2-Fc fusion proteins with picomolar neutralization activity against highly evolved SARS-CoV-2 variants.

Optimized ACE2-Fc fusion proteins with picomolar neutralization activity against highly evolved SARS-CoV-2 variants.

Journal: Protein science : a publication of the Protein Society
Published: October 17, 2025

A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model.

A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model.

Journal: mBio
Published: April 24, 2025

Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters.

Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters.

Journal: Communications biology
Published: January 15, 2025

Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results.

Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results.

Journal: Vaccines
Published: June 14, 2024

Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes.

Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes.

Journal: Nature communications
Published: June 11, 2024

Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.

Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.

Journal: Vaccine
Published: April 23, 2024

Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy.

Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: January 16, 2024

Plitidepsin as an Immunomodulator against Respiratory Viral Infections.

Plitidepsin as an Immunomodulator against Respiratory Viral Infections.

Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: June 26, 2023

Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2.

Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 28, 2023

Self-sampling monkeypox virus testing in high-risk populations, asymptomatic or with unrecognized Mpox, in Spain.

Self-sampling monkeypox virus testing in high-risk populations, asymptomatic or with unrecognized Mpox, in Spain.

Journal: Nature communications
Published: February 06, 2023

A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity.

A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity.

Journal: Nature communications
Published: January 25, 2023

β-Cyclodextrins as affordable antivirals to treat coronavirus infection.

β-Cyclodextrins as affordable antivirals to treat coronavirus infection.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: January 13, 2023
Showing 1-12 of 41

Last Updated: 09/26/2026